Search Results - "Matthews, Jennifer R"

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Sympathetic Activation Promotes Sodium Glucose Co-Transporter-1 Protein Expression in Rodent Skeletal Muscle by Matthews, Jennifer R, Herat, Lakshini Y, Schlaich, Markus P, Matthews, Vance B

    Published in Biomedicines (01-07-2024)
    “…The hyperactivation of the sympathetic nervous system (SNS) is linked to obesity, hypertension, and type 2 diabetes, which are characterized by elevated…”
    Get full text
    Journal Article
  2. 2

    Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy by Herat, Lakshini Y, Matthews, Jennifer R, Rakoczy, Elizabeth P, Schlaich, Markus P, Matthews, Vance B

    Published in Frontiers in bioscience (Landmark. Print) (27-04-2023)
    “…Diabetic retinopathy (DR) is a leading cause of end-stage blindness globally and is arguably one of the most disabling complications of both Type 1 and Type 2…”
    Get full text
    Journal Article
  3. 3

    Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy by Herat, Lakshini Y, Matthews, Jennifer R, Ong, Wei E, Rakoczy, Elizabeth P, Schlaich, Markus P, Matthews, Vance B

    Published in Frontiers in bioscience (Landmark. Print) (12-12-2022)
    “…Diabetic retinopathy (DR) is a major cause of blindness globally. Sodium Glucose Cotransporter-2 (SGLT2) inhibitors have been demonstrated to exert cardiorenal…”
    Get full text
    Journal Article
  4. 4

    SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging by Matthews, Jennifer R., Herat, Lakshini Y., Magno, Aaron L., Gorman, Shelley, Schlaich, Markus P., Matthews, Vance B.

    Published in Biomedicines (18-11-2020)
    “…Recent preclinical data show that sodium glucose cotransporter 2 (SGLT2) inhibitors are able to reduce weight gain and induce beiging in white adipose tissue…”
    Get full text
    Journal Article